Technical Analysis for NUVB - Nuvation Bio Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 2.58 | -0.39% | -0.01 |
NUVB closed down 0.39 percent on Wednesday, November 20, 2024, on 1.94 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
50 DMA Support | Bullish | 0.00% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
20 DMA Support | Bullish | -0.39% | |
50 DMA Support | Bullish | -0.39% | |
Wide Bands | Range Expansion | -0.39% | |
Gapped Down | Weakness | -0.39% |
Alert | Time |
---|---|
Possible NR7 | about 18 hours ago |
Possible Inside Day | about 18 hours ago |
1.5x Volume Pace | about 18 hours ago |
Reversed from Down | about 22 hours ago |
20 DMA Support | about 22 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 10/31/2024
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Prostate Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Prostate Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.1598 |
52 Week Low | 1.22 |
Average Volume | 1,848,944 |
200-Day Moving Average | 2.78 |
50-Day Moving Average | 2.52 |
20-Day Moving Average | 2.54 |
10-Day Moving Average | 2.76 |
Average True Range | 0.18 |
RSI (14) | 50.25 |
ADX | 20.83 |
+DI | 24.09 |
-DI | 23.86 |
Chandelier Exit (Long, 3 ATRs) | 2.54 |
Chandelier Exit (Short, 3 ATRs) | 2.72 |
Upper Bollinger Bands | 3.06 |
Lower Bollinger Band | 2.02 |
Percent B (%b) | 0.54 |
BandWidth | 40.68 |
MACD Line | 0.06 |
MACD Signal Line | 0.06 |
MACD Histogram | 0.0001 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.76 | ||||
Resistance 3 (R3) | 2.75 | 2.68 | 2.73 | ||
Resistance 2 (R2) | 2.68 | 2.64 | 2.69 | 2.72 | |
Resistance 1 (R1) | 2.63 | 2.61 | 2.60 | 2.64 | 2.71 |
Pivot Point | 2.56 | 2.56 | 2.55 | 2.57 | 2.56 |
Support 1 (S1) | 2.51 | 2.52 | 2.48 | 2.52 | 2.45 |
Support 2 (S2) | 2.44 | 2.49 | 2.45 | 2.44 | |
Support 3 (S3) | 2.39 | 2.44 | 2.43 | ||
Support 4 (S4) | 2.40 |